← Back to Clinical Trials
Recruiting NCT06979089

NCT06979089 Implementation of DWM in Dutch SMEs

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06979089
Status Recruiting
Phase
Sponsor VU University of Amsterdam
Condition Anxiety
Study Type INTERVENTIONAL
Enrollment 518 participants
Start Date 2025-05-19
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Doing What Matters in Times of Stress

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 518 participants in total. It began in 2025-05-19 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this cluster randomized controlled trial is to explore if mental health in Dutch small and medium-sized enterprises (SMEs) can be improved by the World Health Organization's online program Doing What Matters in Times of Stress (DWM). The main questions it aims to answer are: * Does DWM improve the mental health of employees working in Dutch SMEs? * Does DWM improve work-related outcomes in employees working in Dutch SMEs? * How can DWM be implemented at a large scale in Dutch SMEs? Researchers will compare two groups to see if the DWM program is effective. One group will receive the DWM program and Care-as-Usual (group 1), and the other group will receive Care-as-Usual only (group 2). Participants will: * Follow the online DWM program for 5 weeks (only group 1). * Take part in 6 telephone appointments with a facilitator (helper) that provides extra support to complete the program (only group 1). * Complete 3 sets of questionnaires. Each set of questionnaire takes about 15 minutes to be completed (group 1 and group 2).

Eligibility Criteria

Inclusion Criteria (SMEs): * Having 10 to 250 employees * Being located in the Netherlands * (In case of insufficient recruitment among SMEs, a mitigation strategy is to recruit individual departments from larger organizations) Inclusion Criteria (Individual participants): * 18 years or older * Having elevated levels of psychological distress (Kessler Psychological Distress Scale; K10 scores \> 15.9) * Sufficient literacy and mastery (written and spoken) of one of the languages the DWM intervention is being delivered in (i.e., Dutch or English) * Having access to an electronic device with internet access to follow the intervention * Written informed consent before entering the study Exclusion Criteria (Individual participants): * Imminent suicide risk, or expressed acute needs or protection risks that require immediate follow-up * Currently receiving specialized psychological treatment (e.g., EMDR or CBT) at the time of screening * In case of current psychotropic medication use: being on an unstable dose for at least 2 months or a change in dosage over the past 2 months. * Having participated in the preceding ASCEND trial as supervisor (see NCT ID: NCT06989398)

Contact & Investigator

Central Contact

Cătălin Gherdan

✉ c.gherdan@vu.nl

📞 +31 20 59 82587

Principal Investigator

Marit E. Sijbrandij

PRINCIPAL INVESTIGATOR

VU University of Amsterdam

Frequently Asked Questions

Who can join the NCT06979089 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06979089 currently recruiting?

Yes, NCT06979089 is actively recruiting participants. Contact the research team at c.gherdan@vu.nl for enrollment information.

Where is the NCT06979089 trial being conducted?

This trial is being conducted at Amsterdam, Netherlands.

Who is sponsoring the NCT06979089 clinical trial?

NCT06979089 is sponsored by VU University of Amsterdam. The principal investigator is Marit E. Sijbrandij at VU University of Amsterdam. The trial plans to enroll 518 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology